JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Clinical Characteristics, Prognostic Factors and Influence of Prophylaxis in Children with Pneumocystis jirovecii Pneumonia
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
  • Journal title : Pediatric Infection and Vaccine
  • Volume 23, Issue 1,  2016, pp.31-39
  • Publisher : The Korean Society of Pediatric Infectious Diseases
  • DOI : 10.14776/piv.2016.23.1.31
 Title & Authors
Clinical Characteristics, Prognostic Factors and Influence of Prophylaxis in Children with Pneumocystis jirovecii Pneumonia
Kim, Seohee; Yoo, Reenar; Sung, Hungseop; Lee, Jina;
  PDF(new window)
 Abstract
Purpose: The aim of this study was to investigate the prognostic factors for Pneumocystis jirovecii pneumonia (PCP) and to evaluate the influence of PCP prophylaxis in pediatric patients. Methods: From January 2002 to April 2015, patients aged <18 years with a diagnosis of confirmed PCP at our institute were reviewed retrospectively. Clinical characteristics and outcomes were compared according to the groups with or without PCP prophylaxis. Risk factors associated with PCP-related death were analyzed by logistic regression analysis. Results: During study period, a total of 24 patients were diagnosed with PCP by immunofluorescence assay and/or PCR. The median age of the patients was 5 years (range, 3 months-18 years) and 23 (96%) had immunocompromised conditions including hematologic disorders with or without hematopoietic stem cell transplantation (n
 Keywords
Pneumocystis jirovecii Pneumonia;Prophylaxis;Prognostic factor;
 Language
Korean
 Cited by
 References
1.
Poulsen A, Demeny AK, Bang Plum C, Gjerum Nielsen K, Schmiegelow K. Pneumocystis carinii pneumonia during maintenance treatment of childhood acute lymphoblastic leukemia. Med Pediatr Oncol 2001;37:20-3. crossref(new window)

2.
Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009;15:1143-238. crossref(new window)

3.
Kovacs JA, Gill VJ, Meshnick S, Masur H. New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia. JAMA 2001;286:2450-60. crossref(new window)

4.
Morris A, Lundgren JD, Masur H, Walzer PD, Hanson DL, Frederick T, et al. Current epidemiology of Pneumocystis pneumonia. Emerg Infect Dis 2004;10:1713-20. crossref(new window)

5.
Stern A, Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev 2014;10:Cd005590.

6.
Green H, Paul M, Vidal L, Leibovici L. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIVinfected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc 2007;82:1052-9. crossref(new window)

7.
Proudfoot R, Cox R, Phillips B, Wilne S. UK survey of Pneumocystis jirovecii pneumonia (PJP) prophylaxis use in paediatric oncology patients. Arch Dis Child 2015;100:115. crossref(new window)

8.
Shankar SM, Nania JJ. Management of Pneumocystis jiroveci pneumonia in children receiving chemotherapy. Paediatr Drugs 2007;9:301-9. crossref(new window)

9.
Wang XL, Wang XL, Wei W. Retrospective study of Pneumocystis pneumonia over half a century in mainland China. J Med Microbiol 2011;60:631-8. crossref(new window)

10.
Torres HA, Chemaly RF, Storey R, Aguilera EA, Nogueras GM, Safdar A, et al. Influence of type of cancer and hematopoietic stem cell transplantation on clinical presentation of Pneumocystis jiroveci pneumonia in cancer patients. Eur J Clin Microbiol Infect Dis 2006;25:382-8. crossref(new window)

11.
Roblot F, Godet C, Le Moal G, Garo B, Faouzi Souala M, Dary M, et al. Analysis of underlying diseases and prognosis factors associated with Pneumocystis carinii pneumonia in immunocompromised HIV-negative patients. Eur J Clin Microbiol Infect Dis 2002;21:523-31. crossref(new window)

12.
Kim SJ, Lee J, Cho YJ, Park YS, Lee CH, Yoon HI, et al. Prognostic factors of Pneumocystis jirovecii pneumonia in patients without HIV infection. J Infect 2014;69:88-95. crossref(new window)

13.
Tamai K, Tachikawa R, Tomii K, Nagata K, Otsuka K, Nakagawa A, et al. Prognostic value of bronchoalveolar lavage in patients with non-HIV Pneumocystis pneumonia. Intern Med 2014;53:1113-7. crossref(new window)

14.
Lundberg BE, Davidson AJ, Burman WJ. Epidemiology of Pneumocystis carinii pneumonia in an era of effective prophylaxis:the relative contribution of non-adherence and drug failure. AIDS 2000;14:2559-66. crossref(new window)

15.
World Health Organization: Programme for the Control of Acute Respiratory infections. Acute respiratory infection in children: case management in small hospitals in developing countries. A manual for doctors and other senior health workers. Geneva, Switzerland: World Health Organization, 1990.

16.
Goldstein B, Giroir B, Randolph A. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 2005;6:2-8. crossref(new window)

17.
Zajac-Spychala O, Gowin E, Fichna P, Wysocki J, Fichna M, Kowala-Piaskowska A, et al. Pneumocystis pneumonia in children - the relevance of chemoprophylaxis in different groups of immunocompromised and immunocompetent paediatric patients. Cent Eur J Immunol 2015;40:91-5.

18.
Saltzman RW, Albin S, Russo P, Sullivan KE. Clinical conditions associated with PCP in children. Pediatr Pulmonol 2012;47:510-6. crossref(new window)

19.
Kofteridis DP, Valachis A, Velegraki M, Antoniou M, Christofaki M, Vrentzos GE, et al. Predisposing factors, clinical characteristics and outcome of Pneumonocystis jirovecii pneumonia in HIV-negative patients. J Infect Chemother 2014;20:412-6. crossref(new window)

20.
Iriart X, Challan Belval T, Fillaux J, Esposito L, Lavergne RA, Cardeau-Desangles I, et al. Risk factors of Pneumocystis pneumonia in solid organ recipients in the era of the common use of posttransplantation prophylaxis. Am J Transplant 2015;15:190-9. crossref(new window)

21.
Laursen AL, Mogensen SC, Andersen HM, Andersen PL, Ellermann-Eriksen S. The impact of CMV on the respiratory burst of macrophages in response to Pneumocystis carinii. Clin Exp Immunol 2001;123:239-46. crossref(new window)

22.
Jensen AM, Lundgren JD, Benfield T, Nielsen TL, Vestbo J. Does cytomegalovirus predict a poor prognosis in Pneumocystis carinii pneumonia treated with corticosteroids? A note for caution. Chest 1995;108:411-4. crossref(new window)

23.
Saah AJ, Hoover DR, Peng Y, Phair JP, Visscher B, Kingsley LA, et al. Predictors for failure of Pneumocystis carinii pneumonia prophylaxis. Multicenter AIDS Cohort Study. JAMA 1995;273:1197-202. crossref(new window)

24.
Nahimana A, Rabodonirina M, Zanetti G, Meneau I, Francioli P, Bille J, et al. Association between a specific Pneumocystis jiroveci dihydropteroate synthase mutation and failure of pyrimethamine/sulfadoxine prophylaxis in human immunodeficiency virus-positive and -negative patients. J Infect Dis 2003;188:1017-23. crossref(new window)

25.
Ewald H, Raatz H, Boscacci R, Furrer H, Bucher HC, Briel M. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection. Cochrane Database Syst Rev 2015;4:Cd006150.

26.
Moon SM, Kim T, Sung H, Kim MN, Kim SH, Choi SH, et al. Outcomes of moderate-to-severe Pneumocystis pneumonia treated with adjunctive steroid in non-HIV-infected patients. Antimicrob Agents Chemother 2011;55:4613-8. crossref(new window)

27.
Pareja JG, Garland R, Koziel H. Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. Chest 1998;113:1215-24. crossref(new window)

28.
Barbounis V, Aperis G, Gambletsas E, Koumakis G, Demiris M, Vassilomanolakis M, et al. Pneumocystis carinii pneumonia in patients with solid tumors and lymphomas: predisposing factors and outcome. Anticancer Res 2005;25:651-5.

29.
Guo F, Chen Y, Yang SL, Xia H, Li XW, Tong ZH. Pneumocystis pneumonia in HIV-infected and immunocompromised non-HIV infected patients: a retrospective study of two centers in China. PLoS One 2014;9:e101943. crossref(new window)

30.
Gracia JD, Miravitlles M, Mayordomo C, Ferrer A, Alvarez A, Bravo C, et al. Empiric treatments impair the diagnostic yield of BAL in HIV-positive patients. Chest 1997;111:1180-6. crossref(new window)

31.
Leigh TR, Gazzard BG, Rowbottom A, Collins JV. Quantitative and qualitative comparison of DNA amplification by PCR with immunofluorescence staining for diagnosis of Pneumocystis carinii pneumonia. J Clin Pathol 1993;46:140-4. crossref(new window)

32.
Colangelo G, Baughman RP, Dohn MN, Frame PT. Followup bronchoalveolar lavage in AIDS patients with Pneumocystis carinii pneumonia. Pneumocystis carinii burden predicts early relapse. Am Rev Respir Dis 1991;143:1067-71. crossref(new window)